


PRODUCT: GDC-0623

ALTERNATE NAMES: GDC0623; GDC 0623; 5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide

CATALOG#: B1690-5, -25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₁₆H₁₄FIN₄O₃

MOLECULAR WEIGHT: 456.21

CAS NUMBER: 1168091-68-6

APPEARANCE: Solid powder

SOLUBILITY: DMSO

PURITY: >98%

STORAGE: Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.

DESCRIPTION: GDC-0623 is a potent, ATP-uncompetitive inhibitor of MEK1 (K_i=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC₅₀=42 nM) versus A375 (BRAFV600E, EC₅₀=7 nM).

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Hatzivassiliou G et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. *Nature*. 2013 Sep 12;501(7466):232-6.
2. Takahashi RH et al. Elucidating the Mechanisms of Formation for Two Unusual Cytochrome P450-Mediated Fused Ring Metabolites of GDC-0623, a MAPK/ERK Kinase Inhibitor. *Drug Metab Dispos*. 2015 Dec;43(12):1929-1933.

RELATED PRODUCTS:

- PD184352 (Cat. No. 1585-1, 5, 25)
- EZSolution™ PD184352 (Cat. No. 1871-1)
- PD 98059 (Cat. No. 1666-5)
- EZSolution™ PD 98059 (Cat. No. 1783-5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB-203580 (Cat. No. 1786-1)
- U0126 (Cat. No. 1668-5)
- Sorafenib (Cat. No. 1594-25, 100)
- VX-702 (Cat. No. 1598-1, 5)

USAGE: **FOR RESEARCH USE ONLY! Not to be used in humans**